Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
Juan P. Frías, Pernille Auerbach, Harpreet S. Bajaj, Yasushi Fukushima, Ildiko Lingvay, Stanislava Macura, ANETTE L. SØNDERGAARD, Tsvetalina Tankova, Nikolaοs Tentolouris, John B. Buse
Topics & Concepts
SemaglutideMedicineDiscontinuationType 2 diabetesSulfonylureaInternal medicineRandomized controlled trialDiabetes mellitusMetforminPhysical therapyInsulinEndocrinologyLiraglutideDiabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsBariatric Surgery and Outcomes